huamin qin

Dr. huamin qin

Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
XCxinyuan Cui
xinyuan Cui
XPxiaosong Pei
xiaosong Pei
HWhao Wang
hao Wang
PFPing Feng
Ping Feng
HQhuamin qin
huamin qin
JLJiwei Liu
Jiwei Liu
Peritoneal metastasis is the main cause of poor prognoses and high mortality in ovarian cancer patients. Abnormal protein glycosylation modification is associated with cancer malignancy. Elevated α1,3-mannosyltransferase 3 (ALG3), which catalyzes the α1,3-mannosylation of glycoproteins, has been found in some malignant tumors. However, the pathological significance of ALG3 and its regulatory mechanism in ovarian cancer metastasis is unclear. The results showed that the level of ALG3/α1,3-mannosylation was higher in human ovarian cancer tissues compared with normal ovarian tissues, as measured by Lectin chip, Western blot and Lectin blot analyses, as well as ovarian tissue microarray analysis. ALG3 was also correlated with the poor prognosis of ovarian cancer patients, according to survival analysis. The downregulation of ALG3 decreased the proliferation, stemness and peritoneal metastasis of ovarian cancer cells. The increase in urokinase plasminogen activator receptor (uPAR) α1,3-mannosylation catalyzed by ALG3 enhanced urokinase plasminogen activator (uPA)/uPAR activation and the interaction of uPAR with a disintegrin and metalloproteinase 8 (ADAM8), which promoted ovarian cancer peritoneal metastasis via the ADAM8/Ras/ERK pathway. Furthermore, decreased ALG3 suppressed ascites formation and the peritoneal metastasis of ovarian cancer cells in mice. This study highlights ALG3 as a potential diagnostic biomarker and prospective therapeutic target for ovarian cancer.

17 June 2022 in Pathology - Research and Practice
Verified
Journal Article
Closed access
HLHaoran Li
Haoran Li
JLJianwei Liu
Jianwei Liu
NFNingning Fan
Ningning Fan
HWHao Wang
Hao Wang
ATAline M. Thomas
Aline M. Thomas
HQhuamin qin
huamin qin

1 November 2022 in Clinical Neuropathology
Verified
Journal Article
Closed access
WWWenbo Wang
Wenbo Wang
YZYunkun Zhang
Yunkun Zhang
YDYang Dong
Yang Dong
SLShen Li
Shen Li
HQhuamin qin
huamin qin
Primary histiocytic sarcoma of the central nervous system is a rare lym-phohematopoietic tumor originating from histiocytes. Here we report such a case with somatic NF2 mutation. Based on imaging studies, a 24-year-old woman presented with a homogeneously enhancing lesion in the right parietal lobe region and without other organ involvement. Histological analy-sis showed that the pleomorphic tumor cells were loosely arranged, and the neoplastic cells are characterized by abundant eosino-philic cytoplasm, highly atypical nuclei, and prominent nucleoli. The lesional cells were immunoreactive with antibodies against CD68KP1, CD163 focally, lysozyme, and BRAF V600E. NGS-based genetic profiling re-vealed a pathogenic somatic NF2 (p.R196*) mutation. Additionally, BRAF (p.V600E), PDGFRA (p.V561D), BRCA1 (p.H437Q, VUS), and BRCA2 (p.E2343A, VUS) mutations were detected. However, the tumor did not re-spond to apatinib and anlotinib treatment, and the patient died 10 months after the ini-tial diagnosis.